ClinicalTrials.gg
RecruitingNCT06884618Updated Sep 28, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

A Phase 1 interventional study of RO7673396 in Neoplasms, sponsored by Hoffmann-La Roche. Recruiting at 25 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Updated Sep 28, 2026First site in United KingdomEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
405
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and of other doses of interest for future development in selected solid tumor indications.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • RAS Mutated Solid Tumors
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 405 is above the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Sep 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented, locally advanced, recurrent, or incurable solid tumors
  • Participants with according to v1.1 assessed by the investigator
  • (ECOG) performance status of 0 or 1
  • ≥12 weeks
  • Adequate hematologic and end-organ function
  • Confirmed presence of the RAS mutation(s)

Exclusion criteria

Exclusion Criteria:

  • Current participant or enrollment in another interventional clinical trial
  • Known or medical to any component of RO7673396 formulation
  • nausea and vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate study treatment absorption
  • Known and untreated, or active central nervous system (CNS)
  • Participants with chronic diarrhea, short bowel syndrome or significant upper gastrointestinal (GI) surgery including gastric resection, a history of inflammatory bowel disease (IBD)
  • Treatment with chemotherapy, immunotherapy, biologic therapy, or an agent as anti-cancer therapy within 4 weeks or five half-lives prior to initiation of study treatment
  • Participants who are on acid-reducing agents and unable to safely discontinue them as required in the study
  • Major surgical procedure within 28 days prior to initiation of study treatment, or incomplete recovery from surgery that would interfere with the determination of safety or efficacy of study treatment, or anticipation of need for a major surgical procedure during the study
  • A history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, non-infectious ILD/pneumonitis, or current evidence of active pneumonitis or ILD on screening chest CT scan
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  • Known liver disease
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
405 participants (estimated)

Study arms

  • Experimental
    Stage I

    Participants with advanced solid tumors harboring RAS mutations will receive multiple ascending doses of RO7673396, as per a pre-defined dosing regimen until unacceptable toxicity or disease progression (PD) and/or loss of clinical benefit as determined by the investigator.

    Drug: RO7673396

  • Experimental
    Stage II

    Participants with advanced solid tumors harboring RAS mutations will receive RO7673396 at the dose determined in Stage 1, until unacceptable toxicity or PD and/or loss of clinical benefit as determined by the investigator.

    Drug: RO7673396

Interventions

  • DrugRO7673396

    RO7673396 will be administered as per the schedule specified in the protocol.

06

What researchers measure

Primary outcomes

  1. Stage I: Number of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 40 months

  2. Stage I: Number of Participants With Dose-limiting Toxicities (DLTs)

    Time frame: Up to Day 21

  3. Stage II: Objective Response Rate (ORR) as Assessed by the Investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)

    Time frame: Up to approximately 40 months

Secondary outcomes

  1. Plasma Concentrations of RO7673396 and its Metabolite(s)

    Time frame: Up to approximately 49 months

  2. Stage I: ORR as Assessed by the Investigator per RECIST V1.1

    Time frame: Up to approximately 49 months

  3. Stage I and II: Duration of Response (DOR) as Assessed by the Investigator per RECIST V1.1

    Time frame: Up to approximately 49 months

  4. Stage I and II: Progression-free Survival (PFS) as Assessed by the Investigator per RECIST V1.1

    Time frame: Up to approximately 49 months

07

Study locations

25 of 25 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Aug 2028, 40 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 40 months is close to that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 19, 2025
StartActual
Apr 30, 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
May 25, 2029
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 1 site removed — first site in United Kingdom
Show 5 added (2 Spain, 2 United Kingdom, 1 United States)
  • UCHealth Lung Cancer Clinic - Anschutz Medical Campus - PPDS · Aurora, United States
  • Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON · Barcelona, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • New Queen Elizabeth Hospital Birmingham · Birmingham, United Kingdom
  • St Bartholomew's Hospital · London, United Kingdom
Show 1 removed
  • University of Colorado - Anschutz Medical Campus - PPDS · Aurora, United States
Sep 28, 2026
Eligibility
1 exclusion criterion added
What changed in the criteria
Exclusion criteria
  • AddedA history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, non-infectious ILD/pneumonitis, or current evidence of active pneumonitis or ILD on screening chest CT scan
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    5 sites added, 1 site removed — first site in United Kingdom
    Show 5 added (2 Spain, 2 United Kingdom, 1 United States)
    • UCHealth Lung Cancer Clinic - Anschutz Medical Campus - PPDS · Aurora, United States
    • Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON · Barcelona, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • New Queen Elizabeth Hospital Birmingham · Birmingham, United Kingdom
    • St Bartholomew's Hospital · London, United Kingdom
    Show 1 removed
    • University of Colorado - Anschutz Medical Campus - PPDS · Aurora, United States
    Eligibility 1 exclusion criterion added
    What changed in the criteria
    Exclusion criteria
    • AddedA history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, non-infectious ILD/pneumonitis, or current evidence of active pneumonitis or ILD on screening chest CT scan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06884618
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Apr 30, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
May 25, 2029 (estimated)
Last update
Sep 28, 2026

Study contacts

Reference Study ID Number: YO45758 https://forpatients.roche.com/
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S.)
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion